Cel­gene goes all-out on neu­rode­gen­er­a­tion and Alzheimer’s, trig­ger­ing block­buster deal with $150M in cash for Prothena

Af­ter qui­et­ly build­ing up an ex­pe­ri­enced team of in­ves­ti­ga­tors to tack­le neu­rode­gen­er­a­tion, Cel­gene has be­gun to ag­gres­sive­ly in-li­cense new drugs that can go af­ter Alzheimer’s and oth­er key dis­eases in the field.

Just days af­ter Cel­gene front­ed $50 mil­lion for a dis­cov­ery deal with Vi­vid­ion Ther­a­peu­tics that in­cludes neu­rode­gen­er­a­tion, the big biotech has now lined up op­tions on three pre­clin­i­cal neu­rode­gen­er­a­tion drug projects part­nered with Prothena. At the head of the list is a tau pro­gram, one of the key cul­prits that sci­en­tists be­lieve is close­ly linked with the de­vel­op­ment of Alzheimer’s.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.